^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Merkel Cell Carcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    06/29/2020
    Excerpt:
    KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated...for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    10/02/2019
    Excerpt:
    NCCN Recommendations for Selection of Systemic Therapy for Distant Metastatic Disease…3 checkpoint immunotherapies (avelumab, pembrolizumab, and nivolumab) recommended by NCCN as options for metastatic MCC…